KYMR
Kymera Therapeutics, Inc.
$114.16
-5.08 (-4.26%)
At close · Jul 8
Market Cap
$9.39B
Shares
82,257,588
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$39.21M
-16.7%
FY2025
Net Income
-$311.35M
-39.1%
FY2025
Gross Margin
0%
0pp
FY2025
Operating Margin
-891.07%
-335.2pp
FY2025
Diluted EPS
-$3.69
-23.8%
FY2025
Operating Cash Flow
-$232.89M
-19.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $51.48M | $39.21M | $47.07M | $78.59M | $46.83M | $72.83M | $34.03M | $2.93M | |
| $51.48M | $39.21M | $47.07M | $78.59M | $46.83M | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | — | — | — | |
| — | 0% | 0% | 0% | 0% | — | — | — | |
| $334.48M | $316.57M | $240.25M | $189.08M | $164.25M | $137.02M | $62.11M | $37.16M | |
| $72.27M | $68.19M | $63.53M | $55.04M | $43.83M | $36.35M | $18.23M | $7.98M | |
| — | $8.31M | $7.37M | $3.57M | $2.98M | $2.4M | $1.76M | $825K | |
| $410.6M | $388.61M | $308.71M | $244.12M | $208.08M | $173.36M | $80.34M | $45.14M | |
| -$359.13M | -$349.4M | -$261.64M | -$165.53M | -$161.26M | -$100.53M | -$46.3M | -$42.21M | |
| — | -891.07% | -555.82% | -210.62% | -344.37% | -138.03% | -136.05% | -1438.48% | |
| — | -$341.09M | -$254.26M | -$161.97M | -$158.28M | -$98.13M | -$44.54M | -$41.38M | |
| $44.12M | $38.05M | $37.78M | $18.57M | $6.45M | $313K | $711K | $959K | |
| — | -$311.35M | — | — | — | — | — | — | |
| — | $0 | — | — | $0 | $0 | $0 | $0 | |
| -$315M | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -$100.22M | -$45.59M | -$41.25M | |
| — | -794.04% | -475.57% | -186.99% | -330.6% | -137.6% | -133.96% | -1405.79% | |
| -$315M | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -$100.22M | -$54.64M | -$41.25M | |
| -$319.14M | -$308.07M | -$224.79M | -$142.57M | -$159.1M | -$100.75M | -$45.73M | -$41.24M | |
| USD/shares | — | -$3.69 | -$2.98 | -$2.52 | -$2.87 | -$2.09 | -$3.15 | — |
| USD/shares | — | -$3.69 | -$2.98 | -$2.52 | -$2.87 | -$2.09 | -$3.15 | — |
| shares | — | 84.49M | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 1.7M |
| shares | — | 84.49M | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 1.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.